Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

Tetracycline clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 8 trials in our China and Taiwan registers that name Tetracycline as an intervention. Synced 9 Nov 2026
8Current trials
5Recruiting now
6Lead sponsors
2Country registers
At a glance

Tetracycline is named as an intervention in 8 current clinical trials in our China and Taiwan registers. 5 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Yongquan Shi (2). The most-studied condition is Helicobacter Pylori Infection.

Where Tetracycline is approved

All regulators →

Of the three regulators tracked here, the first to approve Tetracycline was the US, on 19 Nov 1953. It is approved in 2 of the 3 regulators tracked here.

USUnited States (FDA)
19 Nov 1953
Achromycin
NDA050273 on Drugs@FDA
First original NDA/BLA approval
EUEuropean Union (EMA)
No centralised EU authorisation (it may be authorised nationally)
First centralised authorisation
CACanada (Health Canada)
8 Jul 1997
Actisite
Notice of Compliance 4145
First new-drug NOC

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Tetracycline

All medicines →
ENNHS England
£1.4m
14,971 items dispensed, Sep 2025 to Aug 2026
+19% on the previous 12 months
Net ingredient cost, community prescriptions
USUS Medicaid
$7.3m
60,940 prescriptions in 2025 · Tetracycline Hydrochloride, tetracycline hydrochloride
+128% on 2024
Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Tetracycline works

All drug targets →
  • Bacterial 70S ribosome inhibitor Inhibitor
    ChEMBL only
Diseases it has been tested for in clinical trials, by furthest phase
  • Helicobacter pylori infectious diseasePhase 3
  • Chronic periodontitisPhase 3
  • Inclusion conjunctivitisPhase 3
  • Bone disorderPhase 2/3
  • FatiguePhase 2
  • Lyme diseasePhase 2
  • MALT lymphomaPhase 2
  • Gastric lymphomaPhase 2
  • Gastric mucosa-associated lymphoid tissue lymphomaPhase 2
  • PeriodontitisPhase 2
11 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1440, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 10927, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Tetracycline

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • IE
    Ireland: 1 product on the HPRA list
    Each product record links to the HPRA, which publishes the leaflet and SmPC.
  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Tetracycline

ATC codes
S03AA02, S02AA08, S01AA09, J01AA07, D06AA04, A01AB13
ChEMBL
CHEMBL1440
DrugBank
DB00759
PubChem CID
54675776
CAS number
60-54-8
FDA UNII
F8VB5M810T
Wikidata
Q193045
Wikipedia
Tetracycline

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

  • Recruiting563%
  • Not yet open113%
  • By invitation225%

Trials by phase

  • Phase 4788%
  • Not applicable113%
01

Clinical trials of Tetracycline

8 trials
StudyPhaseStatusLead sponsorRegisters
Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection
NCT05332444 · Helicobacter Pylori Infection
Phase 4 Recruiting National Taiwan University Hospital Taiwan
Doxycycline for Helicobacter Pylori Rescue Treatment
NCT05874570 · ClinicalTrials.gov ↗ · Helicobacter Pylori Infection
Phase 4 Recruiting Shanghai Jiao Tong University School of Medicine China
Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication
NCT06723197 · ClinicalTrials.gov ↗ · HELICOBACTER PYLORI INFECTIONS
Phase 4 Recruiting Shandong University China
Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial
NCT07068607 · ClinicalTrials.gov ↗ · Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer
Phase 4 Recruiting Yongquan Shi China
Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment
NCT07139366 · ClinicalTrials.gov ↗ · Gastritis, Dyspepsia, Helicobacter Pylori Infection
Phase 4 Recruiting Yongquan Shi China
Efficacy And Safety of Bismuth-Tetracycline-Rabeprazole Triple For First-Line Eradication of Helicobacter Pylori Infection
NCT07788053 · ClinicalTrials.gov ↗ · Helicobatcer Pylori, First-Line Eradication
Not applicable Not yet open Chih-An Shih, MD Taiwan
The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication
NCT04527055 · ClinicalTrials.gov ↗ · Helicobacter Pylori Infection, Dysbiosis, Probiotics
Phase 4 By invitation National Cheng-Kung University Hospital Taiwan
Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males
NCT06509139 · ClinicalTrials.gov ↗ · Helicobacter Pylori Infection, Sex, Bismuth Quadruple Therapy
Phase 4 By invitation National Cheng-Kung University Hospital Taiwan

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Tetracycline across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

1 single-substance product containing Tetracycline on the HPRA medicines list.

All 1 Irish product →

Supply shortages

No entry for Tetracycline in the EMA, FDA or German BfArM shortage lists we track.

03

Conditions studied with Tetracycline

12 conditions
Helicobacter Pylori Infection5Gastritis1Dyspepsia1Gastric Cancer1Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer1HELICOBACTER PYLORI INFECTIONS1Helicobatcer Pylori1First-Line Eradication1Sex1Bismuth Quadruple Therapy1Dysbiosis1Probiotics1
04

Sponsors

lead sponsor per trial
Lead sponsorTrials
Yongquan Shi2
National Cheng-Kung University Hospital2
Shanghai Jiao Tong University School of Medicine1
Shandong University1
Chih-An Shih, MD1
National Taiwan University Hospital1
05

By country register

RegisterTrialsRecruiting
Clinical trials in China44
Clinical trials in Taiwan41

A trial with sites in more than one country appears in each of those registers.

06

Related compounds

07

Questions about Tetracycline trials

How many clinical trials are testing Tetracycline?

8 current trials in our China and Taiwan registers name Tetracycline as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Tetracycline trials recruiting patients?

Yes. 5 of the 8 trials are recruiting: 4 with sites in China and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Tetracycline clinical trials?

Yongquan Shi (2), National Cheng-Kung University Hospital (2), Shanghai Jiao Tong University School of Medicine (1) and Shandong University (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Is Tetracycline licensed in Ireland?

Yes. The HPRA medicines list includes 1 single-substance product containing Tetracycline, for example Tetralysal 300 mg hard capsules (IMED Healthcare Ltd.,). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Tetracycline shortage?

Not in the lists we track: Tetracycline has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tetracycline works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tetracycline works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tetracycline (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.